Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure... Am J Cardiovasc Drugs (2018) 18:205–211 https://doi.org/10.1007/s40256-017-0256-x ORIGINAL RESEARCH ARTICLE A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin- Converting Enzyme Inhibitors in the USA 1 2 1 1 1 • • • • • Thy P. Do Arpamas Seetasith Rossella Belleli Raymond G. Schlienger Stefano Corda 2 1 1 • • Chakkarin Burudpakdee Hendrik J. Streefkerk Sigrid Behr Published online: 24 November 2017 Springer International Publishing AG, part of Springer Nature 2017 Abstract 205 days). The 1-year incidence of angioedema per 1000 Introduction Real-world evidence on the risk of angioe- patient-years was 3.3 [95% confidence interval (CI) dema associated with angiotensin-converting enzyme 2.4–4.5]. The incidence was higher in Black [6.2 (95% CI inhibitors (ACEIs) in patients with heart failure (HF) is 3.1–12.5)] than in non-black [2.9 (95% CI 2.1–4.1)] scarce. patients, higher in women [5.2 (95% CI 3.4–7.9)] than in Objective This non-interventional study aimed to estimate men [2.3 (95% CI 1.5–3.6)], and greatest in the first the incidence of and risk factors for angioedema in patients 30 days of ACEI therapy. with HF initiating an ACEI in real-world practice. Conclusions The risk of angioedema in patients with HF Methods http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/a-database-cohort-study-to-assess-the-risk-of-angioedema-among-0aZ4K7D4xf
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-017-0256-x
pmid
29177815
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2018) 18:205–211 https://doi.org/10.1007/s40256-017-0256-x ORIGINAL RESEARCH ARTICLE A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin- Converting Enzyme Inhibitors in the USA 1 2 1 1 1 • • • • • Thy P. Do Arpamas Seetasith Rossella Belleli Raymond G. Schlienger Stefano Corda 2 1 1 • • Chakkarin Burudpakdee Hendrik J. Streefkerk Sigrid Behr Published online: 24 November 2017 Springer International Publishing AG, part of Springer Nature 2017 Abstract 205 days). The 1-year incidence of angioedema per 1000 Introduction Real-world evidence on the risk of angioe- patient-years was 3.3 [95% confidence interval (CI) dema associated with angiotensin-converting enzyme 2.4–4.5]. The incidence was higher in Black [6.2 (95% CI inhibitors (ACEIs) in patients with heart failure (HF) is 3.1–12.5)] than in non-black [2.9 (95% CI 2.1–4.1)] scarce. patients, higher in women [5.2 (95% CI 3.4–7.9)] than in Objective This non-interventional study aimed to estimate men [2.3 (95% CI 1.5–3.6)], and greatest in the first the incidence of and risk factors for angioedema in patients 30 days of ACEI therapy. with HF initiating an ACEI in real-world practice. Conclusions The risk of angioedema in patients with HF Methods

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Nov 24, 2017

References

  • Epidemiology of heart failure
    Roger, VL
  • Heart disease and stroke statistics—2017 update: a report from the American Heart Association
    Benjamin, EJ; Blaha, MJ; Chiuve, SE; Cushman, M; Das, SR; Deo, R
  • 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC
    Ponikowski, P; Voors, AA; Anker, SD; Bueno, H; Cleland, JG; Coats, AJ
  • 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the heart failure society of America
    Yancy, CW; Jessup, M; Bozkurt, B; Butler, J; Casey, DE; Colvin, MM
  • Assessment of 105 patients with angiotensin converting enzyme-inhibitor induced angioedema
    Rasmussen, ER; Buchwald, C; Wadelius, M; Prasad, SC; Kamaleswaran, S; Ajgeiy, KK
  • Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors
    Miller, DR; Oliveria, SA; Berlowitz, DR; Fincke, BG; Stang, P; Lillienfeld, DE
  • Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema
    Brown, NJ; Ray, WA; Snowden, M; Griffin, MR
  • Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system
    Toh, S; Reichman, ME; Houstoun, M; Ross Southworth, M; Ding, X; Hernandez, AF
  • Antihypertensive drug associated angioedema: effect modification by race/ethnicity
    Reichman, ME; Wernecke, M; Graham, DJ; Liao, J; Yap, J; Chillarige, Y
  • Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites
    Burkhart, DG; Brown, NJ; Griffin, MR; Ray, WA; Hammerstrom, T; Weiss, S
  • Incidence and characteristics of angioedema associated with enalapril
    Kostis, JB; Kim, HJ; Rusnak, J; Casale, T; Kaplan, A; Corren, J
  • Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors
    Loftus, PA; Tan, M; Patel, G; Lin, J; Helman, S; Badhey, A
  • Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors
    Makani, H; Messerli, FH; Romero, J; Wever-Pinzon, O; Korniyenko, A; Berrios, RS
  • Statin therapy and risks for death and hospitalization in chronic heart failure
    Go, AS; Lee, WY; Yang, J; Lo, JC; Gurwitz, JH
  • Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study
    McCullough, PA; Philbin, EF; Spertus, JA; Kaatz, S; Sandberg, KR; Weaver, WD
  • Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative and claims data: heart failure
    Saczynski, JS; Andrade, SE; Harrold, LR; Tjia, J; Cutrona, SL; Dodd, KS
  • Recent advances in drug-induced angioedema
    Inomata, N
  • Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development
    Schneeweiss, S; Gagne, JJ; Glynn, RJ; Ruhl, M; Rassen, JA